Expression of LRIG1 and LRIG3 correlates withhuman papillomavirus status and patientsurvival in cervical adenocarcinoma

International Journal of Oncology

Volumn 42, Issue 1, 2013, Pages 247-252

  Muller, Susanne ^a   Lindquist, David ^b   Kanter, Lena ^c   Flores Staino, Carmen ^a   Henriksson, Roger ^b   Hedman, Håkan ^b   Andersson, Sonia ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cervical adenocarcinoma; Human leucine rich repeats and immunoglobulin like domains; Human papillomavirus; Survival

Indexed keywords

LEUCINE RICH REPEAT AND IMMUNOGLOBULIN LIKE DOMAIN 1; LEUCINE RICH REPEAT AND IMMUNOGLOBULIN LIKE DOMAIN 2; LEUCINE RICH REPEAT AND IMMUNOGLOBULIN LIKE DOMAIN 3; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CERVICAL ADENOCARCINOMA; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; UTERINE CERVIX CARCINOMA; WART VIRUS;

ADENOCARCINOMA; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM STAGING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 84873614833     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1702     Document Type: Article

References (36)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
2. Socialstyrelsen Ec: Cancer incidence in Sweden 2008, 2008.
3. Vizcaino AP, Moreno V, Bosch FX, Munoz N, Barros-Dios XM and Parkin DM: International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenosquamous cell carcinomas. Int J Cancer 75: 536-545, 1998. (Pubitemid 28094098)
4. Smith HO, Tiffany MF, Qualls CR and Key CR: The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States - a 24-year population-based study. Gynecol Oncol 78: 97-105, 2000. (Pubitemid 30650338)
5. Bray F, Carstensen B, Moller H, et al: Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev 14: 2191-2199, 2005. (Pubitemid 41603267)
6. Pettersson BF, Andersson S, Hellman K and Hellstrom AC: Invasive carcinoma of the uterine cervix associated with pregnancy: 90 years of experience. Cancer 116: 2343-2349, 2010.
7. Etherington IJ and Luesley DM: Adenocarcinoma in situ of the cervix-controversies in diagnosis and treatment. J Low Genit Tract Dis 5: 94-98, 2001. (Pubitemid 32454551)
8. Gien LT, Beauchemin MC and Thomas G: Adenocarcinoma: a unique cervical cancer. Gynecol Oncol 116: 140-146, 2010.
9. Bosch FX and Munoz N: The viral etiology of cervical cancer. Virus Res 89: 183-190, 2002. (Pubitemid 35351537)
10. Andersson S, Larson B, Hjerpe A, et al: Adenocarcinoma of the uterine cervix: the presence of human papillomavirus and the method of detection. Acta Obstet Gynecol Scand 82: 960-965, 2003. (Pubitemid 37159566)
11. Castellsague X, Diaz M, de Sanjose S, et al: Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 98: 303-315, 2006. (Pubitemid 43338210)
12. Andersson S, Wallin KL, Hellstrom AC, et al: Frequent gain of the human telomerase gene TERC at 3q26 in cervical adenocarcinomas. Br J Cancer 95: 331-338, 2006. (Pubitemid 44187594)
13. Gur G, Rubin C, Katz M, et al: LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J 23: 3270-3281, 2004. (Pubitemid 39209151)
14. Laederich MB, Funes-Duran M, Yen L, et al: The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases. J Biol Chem 279: 47050-47056, 2004. (Pubitemid 39518360)
15. Miller JK, Shattuck DL, Ingalla EQ, et al: Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer. Cancer Res 68: 8286-8294, 2008.
16. Shattuck DL, Miller JK, Laederich M, et al: LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy. Mol Cell Biol 27: 1934-1946, 2007.
17. Ledda F, Bieraugel O, Fard SS, Vilar M and Paratcha G: Lrig1 is an endogenous inhibitor of Ret receptor tyrosine kinase activation, downstream signaling, and biological responses to GDNF. J Neurosci 28: 39-49, 2008.
18. Hedman H and Henriksson R: LRIG inhibitors of growth factor signalling - double-edged swords in human cancer? Eur J Cancer 43: 676-682, 2007. (Pubitemid 46502902)
19. Powell AE, Wang Y, Li Y, et al: The pan-ErbB negative regulator Lrig1 is an intestinal stem cell marker that functions as a tumor suppressor. Cell 149: 146-158, 2012.
20. Krig SR, Frietze S, Simion C, et al: Lrig1 is an estrogen-regulated growth suppressor and correlates with longer relapse-free survival in ERalpha-positive breast cancer. Mol Cancer Res 9: 1406-1417, 2011.
21. Lindstrom AK, Ekman K, Stendahl U, et al: LRIG1 and squamous epithelial uterine cervical cancer: correlation to prognosis, other tumor markers, sex steroid hormones, and smoking. Int J Gynecol Cancer 18: 312-317, 2008. (Pubitemid 351365217)
22. Tanemura A, Nagasawa T, Inui S and Itami S: LRIG-1 provides a novel prognostic predictor in squamous cell carcinoma of the skin: immunohistochemical analysis for 38 cases. Dermatol Surg 31: 423-430, 2005. (Pubitemid 40489303)
23. Holmlund C, Haapasalo H, Yi W, et al: Cytoplasmic LRIG2 expression is associated with poor oligodendroglioma patient survival. Neuropathology 29: 242-247, 2009.
24. Hedman H, Lindstrom AK, Tot T, Stendahl U, Henriksson R and Hellberg D: LRIG2 in contrast to LRIG1 predicts poor survival in early-stage squamous cell carcinoma of the uterine cervix. Acta Oncol 49: 812-815, 2010.
25. Lindstrom AK, Asplund A and Hellberg D: Correlation between LRIG1 and LRIG2 expressions and expression of 11 tumor markers, with special reference to tumor suppressors, in CIN and normal cervical epithelium. Gynecol Oncol 122: 372-376, 2011.
26. Andersson S, Rylander E, Larson B, et al: Types of human papillomavirus revealed in cervical adenocarcinomas after DNA sequencing. Oncol Rep 10: 175-179, 2003.
27. Guo D, Nilsson J, Haapasalo H, et al: Perinuclear leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1-3) as prognostic indicators in astrocytic tumors. Acta Neuropathol 111: 238-246, 2006.
28. Klussmann JP, Gultekin E, Weissenborn SJ, et al: Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am J Pathol 162: 747-753, 2003. (Pubitemid 36237483)
29. Sano T, Oyama T, Kashiwabara K, Fukuda T and Nakajima T: Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 153: 1741-1748, 1998. (Pubitemid 28550662)
30. Muller S, Flores-Staino C, Skyldberg B, et al: Expression of p16INK4a and MIB-1 in relation to histopathology and HPV types in cervical adenocarcinoma. Int J Oncol 32: 333-340, 2008. (Pubitemid 351188299)
31. Seoud M, Tjalma WA and Ronsse V: Cervical adenocarcinoma: moving towards better prevention. Vaccine 29: 9148-9158, 2011.
32. Tenti P, Romagnoli S, Silini E, et al: Human papillomavirus types 16 and 18 infection in infiltrating adenocarcinoma of the cervix: PCR analysis of 138 cases and correlation with histologic type and grade. Am J Clin Pathol 106: 52-56, 1996. (Pubitemid 26239321)
33. Andersson S, Rylander E, Larsson B, Strand A, Silfversvard C and Wilander E: The role of human papillomavirus in cervical adenocarcinoma carcinogenesis. Eur J Cancer 37: 246-250, 2001. (Pubitemid 32144703)
34. Attner P, Du J, Nasman A, et al: Human papillomavirus and survival in patients with base of tongue cancer. Int J Cancer 128: 2892-2897, 2011.
35. Hammarstedt L, Lindquist D, Dahlstrand H, et al: Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. Int J Cancer 119: 2620-2623, 2006. (Pubitemid 44691317)
36. Krane JF, Granter SR, Trask CE, Hogan CL and Lee KR: Papanicolaou smear sensitivity for the detection of adenocarcinoma of the cervix: a study of 49 cases. Cancer 93: 8-15, 2001.